Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 1,018,995 shares of the stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total value of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at $440,005,883.59. This represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, December 29th, Mayukh Sukhatme sold 311,873 shares of Roivant Sciences stock. The shares were sold at an average price of $21.74, for a total value of $6,780,119.02.
• On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The stock was sold at an average price of $23.09, for a total transaction of $619,527.79.

Roivant Sciences Price Performance

Roivant Sciences stock traded up $0.07 during trading hours on Wednesday, reaching $21.70. The stock had a trading volume of 5,645,046 shares, compared to its average volume of 7,953,955. The company has a fifty day simple moving average of $20.80 and a 200-day simple moving average of $15.71. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $23.47.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several recent analyst reports. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of Roivant Sciences in a report on Thursday, December 18th. HC Wainwright boosted their price target on shares of Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 12th. The Goldman Sachs Group raised their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. JPMorgan Chase & Co. upped their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Finally, Jefferies Financial Group increased their target price on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.19.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently added to or reduced their stakes in ROIV. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the last quarter. Swiss Life Asset Management Ltd bought a new stake in shares of Roivant Sciences in the third quarter worth $217,000. Danske Bank A S purchased a new stake in Roivant Sciences during the third quarter valued at $138,000. XTX Topco Ltd bought a new position in Roivant Sciences in the third quarter valued at about $1,067,000. Finally, Alyeska Investment Group L.P. boosted its position in Roivant Sciences by 326.7% in the third quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock worth $7,481,000 after purchasing an additional 378,589 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.